MedTrace Logo

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

NCT05365438 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

Conditions

Interventions

DRUG

Omega 3-Atorvastatin

Atmeg 2 capsules with 1 pack of Omethyl cutielet

DRUG

Omega 3-Atorvastatin

Atmeg 2 capsules

DRUG

Atorvastatin-Ezetimibe

ezetimibe/atorvastatin 10/20 mg

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    collaborator INDUSTRY

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365438 on ClinicalTrials.gov